Get the Stockscreener App
8.0228
0.99%
-0.0772
Vanda Pharmaceuticals Inc stock is traded at $8.0228, with a volume of 239.80K.
It is down -0.99% in the last 24 hours and up +17.25% over the past month.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
See More
Previous Close:
$8.10
Open:
$8.1
24h Volume:
239.80K
Relative Volume:
0.15
Market Cap:
$473.66M
Revenue:
$192.64M
Net Income/Loss:
$2.51M
P/E Ratio:
153.11
EPS:
0.0524
Net Cash Flow:
$12.42M
1W Performance:
+7.36%
1M Performance:
+17.25%
6M Performance:
+65.70%
1Y Performance:
+81.45%
1-Day Range:
$8.00
$8.27
1-Week Range:
$7.142
$8.27
52-Week Range:
$3.8092
$9.60
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Name
Vanda Pharmaceuticals Inc
Sector
Industry
Phone
202-734-3400
Address
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
8.015 | 478.68M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.00 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.41 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
816.53 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
363.01 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.15 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-25 | Initiated | B. Riley Securities | Buy |
| Oct-31-24 | Initiated | H.C. Wainwright | Buy |
| Jul-11-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-22 | Downgrade | Jefferies | Buy → Hold |
| May-12-21 | Initiated | BofA Securities | Buy |
| Jan-14-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-29-20 | Upgrade | Citigroup | Neutral → Buy |
| Jun-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-20 | Downgrade | Oppenheimer | Perform → Underperform |
| Mar-12-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-19 | Downgrade | Citigroup | Buy → Neutral |
| Aug-01-19 | Upgrade | Citigroup | Neutral → Buy |
| Jul-25-19 | Downgrade | Stifel | Buy → Hold |
| Dec-11-18 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-04-18 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Dec-04-18 | Reiterated | Jefferies | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Sep-21-18 | Resumed | Oppenheimer | Outperform |
| May-23-18 | Initiated | Citigroup | Buy |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Sep-14-17 | Reiterated | Piper Jaffray | Overweight |
| Jun-27-17 | Resumed | Piper Jaffray | Overweight |
| May-26-17 | Initiated | H.C. Wainwright | Buy |
| Apr-12-17 | Initiated | Oppenheimer | Outperform |
| Nov-09-16 | Initiated | Aegis Capital | Buy |
| Oct-06-16 | Resumed | Jefferies | Buy |
View All
Vanda Pharmaceuticals Inc Stock (VNDA) Latest News
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc.VNDA - marketscreener.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc.VNDA - PR Newswire
Vanda Pharmaceuticals (NASDAQ:VNDA) Shares Cross Above Two Hundred Day Moving AverageHere's Why - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc.VNDA - Chartmill
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc.VNDA - FinancialContent
Vanda Stock Drop 10% Premarket After FDA Rejects Jet Lag Drug Application - MSN
Millennium Management LLC Reduces Stake in Vanda Pharmaceuticals Inc - GuruFocus
VNDA: Imminent launches and label expansions position the portfolio for major near-term growth - TradingView — Track All Markets
Lost Money on Vanda Pharmaceuticals Inc. (VNDA)? Contact Levi & Korsinsky About Fraud Investigation - marketscreener.com
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Down 52.3% in December - MarketBeat
Loss Report: How Vanda Pharmaceuticals Inc stock benefits from tech adoptionShort Setup & Weekly High Potential Alerts - Bộ Nội Vụ
Revenue Check: Why Vanda Pharmaceuticals Inc stock remains a top recommendationPortfolio Gains Summary & Fast Gain Stock Tips - Bộ Nội Vụ
Vanda (VNDA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Finviz
Retail Trends: Will Vanda Pharmaceuticals Inc stock attract more institutional investorsProfit Target & Technical Confirmation Trade Alerts - Bộ Nội Vụ
Aug Retail: Why Vanda Pharmaceuticals Inc stock remains a top recommendation2025 Technical Overview & Weekly Consistent Profit Watchlists - Bộ Nội Vụ
Published on: 2026-01-12 16:11:40 - Улправда
What sentiment indicators say about Vanda Pharmaceuticals Inc. stockMarket Sentiment Summary & Weekly High Potential Stock Alerts - Улправда
Published on: 2026-01-08 21:09:38 - ulpravda.ru
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder - Sahm
Can Vanda Pharmaceuticals Inc. (VM4) stock surprise markets with earningsJuly 2025 Spike Watch & Reliable Breakout Forecasts - ulpravda.ru
Is Vanda Pharmaceuticals Inc. stock affected by interest rate hikes2025 Historical Comparison & Fast Entry and Exit Trade Plans - ulpravda.ru
Is Vanda Pharmaceuticals Inc. stock positioned well for digital economyEarnings Recap Report & Reliable Entry Point Alerts - ulpravda.ru
Is Vanda Pharmaceuticals Inc. (VM4) stock good for long term investingWeekly Risk Report & Low Drawdown Trading Techniques - ulpravda.ru
Vanda Pharmaceuticals (VNDA) Faces FDA Setback on HETLIOZ Application - GuruFocus
FDA rejects Vanda's jet lag drug application days after approving motion sickness drug - The Business Journals
How Vanda Pharmaceuticals Inc. stock performs in high volatility marketsJuly 2025 Sector Moves & Low Risk High Win Rate Picks - ulpravda.ru
Vanda Pharmaceuticals (VNDA) Faces Setback with FDA Rejection - GuruFocus
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter o - GuruFocus
Vanda falls as FDA rejects jet lag drug (VNDA:NASDAQ) - Seeking Alpha
Vanda Pharmaceuticals (VNDA) Shares Fall After FDA Decision - GuruFocus
Vanda Faces FDA Setback on HETLIOZ Jet Lag Application - TipRanks
Vanda Stock Drops 10% Premarket After FDA Rejects Jet Lag Drug Application - Stocktwits
Vanda Pharmaceuticals stock falls after FDA rejects jet lag treatment application - Investing.com Canada
Vanda Pharmaceuticals Inc Receives FDA Decision on HETLIOZ® sNDA for Jet Lag - TradingView — Track All Markets
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder – Company AnnouncementFT.com - Financial Times
Vanda Pharmaceuticals Inc. (VNDA) Stock Analysis: Evaluating a 59.54% Potential Upside Amidst Strong Revenue Growth - DirectorsTalk Interviews
Vanda Pharma says FDA is in violation of FDCA regarding its Hetlioz sNDA - The Pharma Letter
FDA pushes back on new drug that aimed to ease jet lag for travelers - Stock Titan
Q1 EPS Estimate for Vanda Pharmaceuticals Raised by Analyst - MarketBeat
FDA Approves Vanda Pharma Motion Sickness Drug, Fuels Upside - Benzinga
Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - MSN
HC Wainwright Analysts Raise Earnings Estimates for VNDA - MarketBeat
FDA Grants Approval to Vanda Pharma’s Motion Sickness Medication, Boosting Growth Potential - Bitget
Assessing Vanda Pharmaceuticals (VNDA) Valuation After FDA Approval Of NEREUS For Motion Sickness - Yahoo Finance
VIX Spike: Can Vanda Pharmaceuticals Inc VM4 stock surprise markets with earningsJuly 2025 Analyst Calls & Capital Efficiency Focused Ideas - moha.gov.vn
VNDA: HC Wainwright & Co. Raises Price Target to $22, Maintains Buy Rating | VNDA Stock News - GuruFocus
Gastric Motility Disorder Drugs Market is expected to reach US$ - openPR.com
Vanda Pharmaceuticals (NASDAQ:VNDA) Upgraded to "Hold" at Wall Street Zen - MarketBeat
US FDA approves Vanda Pharmaceuticals' motion sickness drug - ET Pharma
Vanda Pharmaceuticals: SG&A Takes Off, TAM Doesn’t (Rating Downgrade) (VNDA) - Seeking Alpha
Vanda's tradipitant can significantly reduce nausea in those taking a GLP-1 - MSN
Vanda Pharmaceuticals Inc Stock (VNDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.31%
2.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):